What are the opening hours?

Monday 8am - 5pm Tuesday 9am - 5pm Wednesday 9am - 5pm Thursday 9am - 5pm Friday 9am - 5pm

Ametris - formerly ActiGraph

Home
United States
Pensacola, FL
Ametris - formerly ActiGraph

Ametris is pioneering the digital transformation of clinical research

04/16/2026

Sensor-based digital health technologies (DHTs) are now essential for capturing patient insights in clinical research. However, managing a fragmented ecosystem of various sensors and vendors often creates operational complexity and risks data quality.

The Ametris Connect platform simplifies this by providing a comprehensive library of validated, pre-integrated sensors and wearables, including ECG patches, digital spirometer, pulse oximeter, and more. The platform enables seamless collection of a wide variety of continuous and episodic digital measures through a unified technology platform.

Learn more: https://hubs.la/Q04cnnHx0

04/15/2026

April is Parkinson's Disease Awareness Month. We'd like to take this opportunity to recognize the millions of individuals living with this condition and the urgent need to better understand and measure their daily experiences.

PD remains a uniquely challenging area of drug development. Symptoms can fluctuate throughout the day and vary widely across individuals, making them difficult to capture through traditional, episodic assessments. This measurement gap limits our ability to assess disease burden and treatment impact.

Digital health technologies (DHTs) are helping close this gap by enabling continuous, objective measurement of symptoms in real-world settings.

Explore our Parkinson's Disease Digital Measures Report to better understand the impact of PD symptoms on daily life through the lens of the patient. Inspired by the FDA’s Patient-Focused Drug Development initiative and based on Voice of the Patient interviews, this report outlines the most significant PD symptoms experienced in daily life and key meaningful aspects of health, as well as candidate digital measures to better assess them.

Download the report: https://hubs.la/Q04c80tL0

04/14/2026

Traditional clinical trial endpoints for Huntington’s Disease (HD) are often limited by their episodic nature and may not capture continuous motor and non-motor symptoms. As the therapeutic focus shifts toward early-stage interventions, the industry requires more sensitive, longitudinal, and objective measurement tools to validate treatment efficacy.

We invite you to our upcoming Digital Health Monthly webinar, exploring the current HD research landscape and opportunities to accelerate clinical development by leveraging wearable DHTs to capture symptom fluctuations and disease progression over time.

Speakers will examine existing endpoints, measurement gaps, patient stratification strategies and perspectives on usability, as well as a framework for integrating passive monitoring into HD clinical trial design.

Panelists:
🔹Jamie Adams, PhD – Associate Professor of Neurology, University of Rochester Medical Center
🔹Matthew Roche, PhD – Director, Outcomes Research, CDHI Foundation
🔹Rakesh Pilkar, PhD – Lead of DHT Solutions, Neuroscience, Ametris

Can’t attend? Register to receive the webinar recording after the event: https://hubs.la/Q04bZhwv0

04/06/2026

Digital health technologies are redefining oncology drug development by enabling continuous, objective data collection in real-world settings and bringing the patient experience to the center of trial design. From complex immunotherapies like CAR-T to conditions such as cancer pain and cachexia, DHTs support more patient-centric studies, smarter endpoints, and a faster path to better patient outcomes.

Explore our latest oncology resources page:
https://hubs.la/Q049Cz3r0

03/26/2026

Digital health technologies have the potential to transform clinical trials, yet without careful planning and operational support, their implementation can create complexity, increase site burden, and influence data quality.

The Ametris Connect platform combines validated clinical sensors, state-of-the-art algorithms, ePRO and remote data capture solutions, and seamless study operations to power continuous, patient-focused data collection in modern digital clinical trials.

Check it out today: https://hubs.la/Q048vV290

03/19/2026

Chronic insomnia disorder, marked by ongoing difficulty falling or staying asleep, can have a profound impact on health, daily functioning, and overall quality of life. While cognitive behavioral therapy remains the gold-standard treatment, many patients with chronic insomnia rely on pharmacological options when symptoms persist.

This new case study by Ametris examines a randomized controlled trial to evaluate the effectiveness of a new therapy for chronic insomnia, highlighting how combining patient-reported and objective, real-world digital measures can deliver a more complete picture of treatment impact compared to conventional methods.

Read the full study: https://hubs.la/Q047BB_r0

03/17/2026

Join us on Wednesday, March 25th for our next Digital Health Monthly webinar, Advancing Digital Measures from Scientific Rigor to Real-World Impact!

During the webinar, members of the Ametris Science Team will discuss some of the most impactful scientific insights, regulatory perspectives, and real-world DHT use cases shared at the recent ADDS 2026 scientific meeting in Atlanta.

Register at the link in the comments ⬇️

03/13/2026

Traditional sleep assessments often stop when the sun comes up. But for patients with narcolepsy, IH, or chronic insomnia, Excessive Daytime Sleepiness (EDS) is a 24-hour burden that PSG and diaries frequently miss.

In our latest article, Matt Patterson, PhD, explores how continuous passive monitoring is closing the measurement gap in sleep disorder research.

Check out the full blog article in the comments ⬇️

03/10/2026

Ametris and Signant Health are proud to announce a strategic partnership to advance drug development in central nervous system (CNS) disorders and other complex therapeutic areas. By integrating Ametris’ medical-grade wearable digital health technology with Signant Health’s industry-leading eCOA platform, this collaboration provides biopharma sponsors with a unified solution that combines clinician- and patient-reported outcomes with objective, continuous movement data.

This approach allows for a more complete view of patient function and treatment effects in conditions like Parkinson’s disease, Huntington's disease, and ALS, where capturing subtle changes between traditional assessment timepoints is critical for demonstrating meaningful clinical benefit.

Read the full announcement here: https://hubs.la/Q046bqHF0

Representatives from both Ametris and Signant Health will be at the AD/PD conference next week in Copenhagen. Contact us to schedule a meeting!

03/09/2026

Across three days of discussion, ADDS 2026 brought together regulators, industry leaders, academic researchers, and technology developers to examine how digital health technologies (DHTs) are reshaping clinical research.

Join us on Wednesday, March 25th for a Digital Health Monthly webinar highlighting the most impactful scientific discussions, regulatory perspectives, and real-world use cases shared during the Ametris Digital Data Summit 2026!

📅 Wednesday, March 25
🕒 12:00 PM EST
Speakers: Christine Guo, Sylvain, and Michael P.

Register for the webinar here: https://hubs.la/Q0460XlS0

03/06/2026

Ametris is heading to Medidata NEXT 2026 in New York City next week! Connect with us in advance and talk with Sarah Bell and our newly appointed Chief Product Officer, Mandana Varahrami.

Don’t miss our Sensor Cloud booth session:
📍 Innovation Lounge Station
🕙 Tuesday, March 10th from 10:00 – 11:00 AM EST

Stop by to get a closer look at our integrated wearable solutions and discuss how our partnership can support your upcoming clinical trial.

03/04/2026

Establishing clinical benefit is one of the most challenging and costly steps in developing new treatments for patients with neuromuscular disorders (NMD) that are affected in physical activity, sleep, gait, and mobility.

Our updated Neuromuscular Disorder Digital Endpoint Guide offers guidance into how wearable Digital Health Technology can help clinical researchers unlock continuous, everyday insights.

Access the guide at the link in the comments below!

Address

Pensacola, FL

Opening Hours

Monday	8am - 5pm
Tuesday	9am - 5pm
Wednesday	9am - 5pm
Thursday	9am - 5pm
Friday	9am - 5pm

Telephone

+18503327900

Website

http://www.ametris.com/

Alerts

Be the first to know and let us send you an email when Ametris - formerly ActiGraph posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Ametris - formerly ActiGraph:

Shortcuts

Address
Telephone
Opening Hours
Alerts
Contact The Practice
Claim ownership or report listing

Featured

Assisting Seniors LLC
32503

Want your practice to be the top-listed Clinic in Pensacola?

About Us

ActiGraph's innovative and extensively validated physical activity and sleep monitoring solutions deliver accurate, measurable insights into the real world physiological behaviors of subjects involved in academic research, population health studies, and clinical trials. Trusted by researchers and scientists in more than 90 countries, ActiGraph hardware and software products are the most widely used and extensively validated objective activity monitoring technology available.